Obesity and diabetes treatments are reshaping the pharmaceutical marketplace, especially the GLP-1 agonists. They are the biggest contributor to the growth in drug sales, and four of the top five fastest-growing drugs by sales are the GLP-1 drugs Mounjaro, Zepbound, Wegovy and Ozempic, according to Scott Biggs, director of supplier services at IQVIA.

“The market is really driven by volume over the last 12 months, and we see the GLP-1s are the biggest contributor to growth in the marketplace,” he said during his keynote presentation at the Pharmacy Benefit Management Institute’s annual meeting today in Orlando. “They’ve really shaken up the market. We weren't even looking at this as a top category three years ago.”

Within the diabetes market, the GLP-1 drugs accounted for about 57% of the

See Full Page